Scott B. Ullem Sells 11,250 Shares of Edwards Lifesciences Co. (NYSE:EW) Stock

Edwards Lifesciences Co. (NYSE:EW) CFO Scott B. Ullem sold 11,250 shares of the company’s stock in a transaction on Wednesday, March 26th. The stock was sold at an average price of $70.87, for a total transaction of $797,287.50. Following the sale, the chief financial officer now directly owns 30,387 shares of the company’s stock, valued at $2,153,526.69. The trade was a 27.02 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Edwards Lifesciences Stock Up 0.1 %

EW opened at $71.17 on Friday. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The business has a 50 day moving average price of $71.47 and a two-hundred day moving average price of $70.46. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The company has a market cap of $41.84 billion, a PE ratio of 10.21, a P/E/G ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, research analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Institutional Trading of Edwards Lifesciences

Several hedge funds have recently made changes to their positions in EW. Harbor Capital Advisors Inc. raised its holdings in Edwards Lifesciences by 2.5% during the fourth quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company’s stock worth $824,000 after purchasing an additional 273 shares in the last quarter. Nordea Investment Management AB raised its stake in shares of Edwards Lifesciences by 34.6% during the 4th quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock worth $301,355,000 after buying an additional 1,043,484 shares in the last quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST raised its stake in shares of Edwards Lifesciences by 6.7% during the 4th quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company’s stock worth $355,344,000 after buying an additional 300,000 shares in the last quarter. Sivik Global Healthcare LLC acquired a new stake in shares of Edwards Lifesciences in the 4th quarter valued at approximately $3,702,000. Finally, Avanza Fonder AB purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $4,845,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on EW. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $82.00 to $90.00 in a research report on Monday, December 16th. Stifel Nicolaus upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and boosted their target price for the stock from $75.00 to $90.00 in a report on Thursday, January 30th. Evercore ISI cut their price target on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a report on Wednesday, February 12th. Citigroup boosted their price objective on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Finally, Wolfe Research downgraded Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.